News Snapshot:
BENGALURU (REUTERS) - Bharat Biotech's vaccine was only 50 per cent effective at preventing symptomatic Covid-19 in a high-risk population during a devastating second wave of infections in India this year, data gleaned from hospital workers showed. The real-world study for Covaxin, conducted from April 15 to May 15, compares with a 77.8 per cent effectiveness rate in a late-stage trial of more than 25,000 participants that was conducted November 2020 to January 2021. The new data analysed just over 1,000 Covid-19 cases with a test-negative control case group, matching by age and gender, according to the study, which was...
